{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:07:26Z","timestamp":1794550046428,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032350","name":"Alligator Bioscience","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.106068","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:52:40Z","timestamp":1776804760000},"page":"106068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-in-human study of intravenous bispecific CTLA-4 \u00d7 OX40 antibody (ATOR-1015) in advanced solid malignancies"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6053-3392","authenticated-orcid":false,"given":"V.","family":"Ekstr\u00f6m-Ryd\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yachnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-9003","authenticated-orcid":false,"given":"K.","family":"Staal Rohrberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Enell Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-1250","authenticated-orcid":false,"given":"P.","family":"Ellmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1421-1792","authenticated-orcid":false,"given":"R.","family":"L\u00f8vendahl Eefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-3267","authenticated-orcid":false,"given":"G.J.","family":"Ullenhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2026.106068_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.esmoop.2026.106068_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106068_bib4","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.molonc.2015.10.008","article-title":"Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy","volume":"9","author":"\u015aledzi\u0144ska","year":"2015","journal-title":"Mol Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106068_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106068_bib6","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1007\/s11030-024-10917-6","article-title":"Elucidating CTLA-4\u2019s role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments","volume":"29","author":"Fu","year":"2025","journal-title":"Mol Divers"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.16","article-title":"OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer","volume":"5","author":"Montler","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"100","key":"10.1016\/j.esmoop.2026.106068_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","article-title":"Treg and CTLA-4: two intertwining pathways to immune tolerance","volume":"45","author":"Walker","year":"2013","journal-title":"J Autoimmun"},{"issue":"30","key":"10.1016\/j.esmoop.2026.106068_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106068_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106068_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol. Apr"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-016-1909-3","article-title":"Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation","volume":"66","author":"Ellmark","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106068_bib15","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/0008-5472.CAN-12-4174","article-title":"OX40 is a potent immune-stimulating target in late-stage cancer patients","volume":"73","author":"Curti","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20071341","article-title":"OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection","volume":"205","author":"Piconese","year":"2008","journal-title":"J Exp Med"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106068_bib19","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.4049\/jimmunol.172.8.4821","article-title":"Costimulation of CD8 T cell responses by OX40","volume":"172","author":"Bansal-Pakala","year":"2004","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Vargas","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106068_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0002-9610(97)00139-6","article-title":"Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers","volume":"174","author":"Vetto","year":"1997","journal-title":"Am J Surg"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106068_bib22","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.4049\/jimmunol.161.12.6510","article-title":"Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses","volume":"161","author":"Gramaglia","year":"1998","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106068_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s11912-022-01265-5","article-title":"Current clinical trial landscape of OX40 agonists","volume":"24","author":"Yadav","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106068_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2326-6066.CIR-13-0031-T","article-title":"Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity","volume":"2","author":"Redmond","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106068_bib25","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI64859","article-title":"Depleting tumor-specific Tregs at a single site eradicates disseminated tumors","volume":"123","author":"Marabelle","year":"2013","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106068_bib26","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2026.106068_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70254","article-title":"Do corticosteroids affect immunotherapy efficacy in malignancy? - A systematic review","volume":"13","author":"Byron","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106068_bib29","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106068_bib30","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106068_bib31","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106068_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11523-025-01134-8","article-title":"Dose optimization of elranatamab to mitigate the risk of cytokine release syndrome in patients with multiple myeloma","volume":"20","author":"Elmeliegy","year":"2025","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2372875","article-title":"Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden","volume":"13","author":"Hamida","year":"2024","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106068_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jtho.2023.10.010","article-title":"Five cases of cytokine release syndrome in patients receiving cytotoxic chemotherapy together with nivolumab plus ipilimumab: a case report","volume":"19","author":"Shiraishi","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106068_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004225","article-title":"Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology","volume":"10","author":"Zhou","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008266","article-title":"Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review","volume":"12","author":"Galle","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bcp.12323","article-title":"Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma","volume":"78","author":"Feng","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2026.106068_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155828","article-title":"Interleukin-8: an evolving chemokine","volume":"153","author":"Matsushima","year":"2022","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106068_bib39","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","article-title":"Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106068_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2330113","article-title":"RUBY\u00ae - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties","volume":"16","author":"Nyesiga","year":"2024","journal-title":"MAbs"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:46:02Z","timestamp":1794516362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926000104"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106068","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human study of intravenous bispecific CTLA-4 \u00d7 OX40 antibody (ATOR-1015) in advanced solid malignancies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106068"}}